ATE485270T1 - 2-phenylindole als antagonisten des prostaglandin-d2-rezeptors - Google Patents

2-phenylindole als antagonisten des prostaglandin-d2-rezeptors

Info

Publication number
ATE485270T1
ATE485270T1 AT07799729T AT07799729T ATE485270T1 AT E485270 T1 ATE485270 T1 AT E485270T1 AT 07799729 T AT07799729 T AT 07799729T AT 07799729 T AT07799729 T AT 07799729T AT E485270 T1 ATE485270 T1 AT E485270T1
Authority
AT
Austria
Prior art keywords
phenylindole
prostaglandin
antagonist
receptor
Prior art date
Application number
AT07799729T
Other languages
German (de)
English (en)
Inventor
Zhaoxia Yang
Stephan Reiling
Thaddeus R Nieduzak
Rose M Mathew
Sharon Jackson
Keith J Harris
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Application granted granted Critical
Publication of ATE485270T1 publication Critical patent/ATE485270T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
AT07799729T 2006-07-25 2007-07-20 2-phenylindole als antagonisten des prostaglandin-d2-rezeptors ATE485270T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US82030106P 2006-07-25 2006-07-25
US82030206P 2006-07-25 2006-07-25
US82029906P 2006-07-25 2006-07-25
PCT/US2007/073945 WO2008014186A1 (en) 2006-07-25 2007-07-20 2-phenyl-indoles as prostaglandin d2 receptor antagonists

Publications (1)

Publication Number Publication Date
ATE485270T1 true ATE485270T1 (de) 2010-11-15

Family

ID=38610820

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07799729T ATE485270T1 (de) 2006-07-25 2007-07-20 2-phenylindole als antagonisten des prostaglandin-d2-rezeptors

Country Status (25)

Country Link
US (1) US20090176804A1 (enExample)
EP (1) EP2066628B1 (enExample)
JP (1) JP2009544721A (enExample)
KR (1) KR20090039735A (enExample)
AR (1) AR062051A1 (enExample)
AT (1) ATE485270T1 (enExample)
AU (1) AU2007276885A1 (enExample)
BR (1) BRPI0714554A2 (enExample)
CA (1) CA2659055A1 (enExample)
CL (1) CL2007002163A1 (enExample)
CO (1) CO6190511A2 (enExample)
CR (1) CR10577A (enExample)
DE (1) DE602007010010D1 (enExample)
DK (1) DK2066628T3 (enExample)
EC (1) ECSP099087A (enExample)
GT (1) GT200900016A (enExample)
IL (1) IL196587A0 (enExample)
MA (1) MA30643B1 (enExample)
MX (1) MX2009000830A (enExample)
NO (1) NO20090862L (enExample)
PE (1) PE20080549A1 (enExample)
PT (1) PT2066628E (enExample)
TN (1) TNSN08515A1 (enExample)
TW (1) TW200821286A (enExample)
WO (1) WO2008014186A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2009072576A1 (ja) * 2007-12-04 2011-04-28 サッポロビール株式会社 骨形成促進剤
MX2011005120A (es) * 2008-11-17 2011-05-30 Hoffmann La Roche Acidos naftilaceticos.
SI2558447T1 (sl) 2010-03-22 2015-01-30 Actelion Pharmaceuticals Ltd. Derivati 3-(heteroaril-amino)-1,2,3,4-tetrahidro-9h-karbazola in njihova uporaba kot modulatorji prostaglandinskega receptorja d2
EP2697223B1 (en) 2011-04-14 2016-07-13 Actelion Pharmaceuticals Ltd. 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators
US9797903B2 (en) 2012-10-24 2017-10-24 Winthrop-University Hospital Non-invasive biomarker to identify subject at risk of preterm delivery
JP2015089886A (ja) * 2013-11-06 2015-05-11 国立大学法人名古屋大学 嵩高い置換基を有する化合物を用いた植物成長調整剤
HRP20181555T1 (hr) 2014-03-17 2018-11-30 Idorsia Pharmaceuticals Ltd Derivati azaindol-octene kiseline i njihova uporaba kao modulatora receptora prostaglandina d2
EP3119780B1 (en) 2014-03-18 2018-08-29 Idorsia Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
EA035752B1 (ru) 2015-09-15 2020-08-05 Идорсиа Фармасьютиклз Лтд КРИСТАЛЛИЧЕСКАЯ ФОРМА (S)-2-(8-((5-ХЛОРПИРИМИДИН-2-ИЛ)(МЕТИЛ)-АМИНО)-2-ФТОР-6,7,8,9-ТЕТРАГИДРО-5Н-ПИРИДО[3,2-b]ИНДОЛ-5-ИЛ)УКСУСНОЙ КИСЛОТЫ И СОДЕРЖАЩИЕ ЕЁ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ
US20200264188A1 (en) 2017-09-13 2020-08-20 Progenity, Inc. Preeclampsia biomarkers and related systems and methods
WO2019166628A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
US12168653B2 (en) 2018-03-02 2024-12-17 Inflazome Limited Sulfonamide derivates as NLRP3 inhibitors
EP3759102A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
US12030879B2 (en) 2018-03-02 2024-07-09 Inflazome Limited Sulfonyl acetamides as NLRP3 inhibitors
WO2019166632A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
JP7455762B2 (ja) * 2018-05-09 2024-03-26 グルソックス・バイオテック・アーベー 選択的なＮｏｘ阻害活性を有する新規のスルホンアミド誘導体
EP4070113A4 (en) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS
CN111333516B (zh) * 2020-04-14 2022-09-06 国药集团化学试剂有限公司 一种2-氯-5-溴硝基苯的制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DOP2006000016A (es) * 2005-01-26 2006-07-31 Aventis Pharma Inc 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2.

Also Published As

Publication number Publication date
EP2066628A1 (en) 2009-06-10
KR20090039735A (ko) 2009-04-22
CO6190511A2 (es) 2010-08-19
TNSN08515A1 (en) 2010-04-14
WO2008014186A1 (en) 2008-01-31
DE602007010010D1 (de) 2010-12-02
EP2066628B1 (en) 2010-10-20
PT2066628E (pt) 2010-12-31
IL196587A0 (en) 2009-11-18
CA2659055A1 (en) 2008-01-31
GT200900016A (es) 2010-10-13
AU2007276885A1 (en) 2008-01-31
TW200821286A (en) 2008-05-16
US20090176804A1 (en) 2009-07-09
AR062051A1 (es) 2008-08-10
BRPI0714554A2 (pt) 2013-05-07
MA30643B1 (fr) 2009-08-03
DK2066628T3 (da) 2011-02-07
NO20090862L (no) 2009-02-24
ECSP099087A (es) 2009-02-27
JP2009544721A (ja) 2009-12-17
PE20080549A1 (es) 2008-06-20
CR10577A (es) 2009-03-20
CL2007002163A1 (es) 2008-02-08
MX2009000830A (es) 2009-02-03

Similar Documents

Publication Publication Date Title
ATE485270T1 (de) 2-phenylindole als antagonisten des prostaglandin-d2-rezeptors
ATE481405T1 (de) Thiazolpyrazolopyrimidine als antagonisten des crf1-rezeptors
EP2150115A4 (en) CYCLOPROPYLPYRROLIDINOREXIN Receptor Antagonists
BRPI0913930A2 (pt) antagonistas de receptores de prostaglandinas d2
EP2049110A4 (en) BRAZED DIAZEPANOREXINE RECEPTOR ANTAGONISTS
EP2079466A4 (en) SUBSTITUTED INDOLE COMPOUNDS
ATE509927T1 (de) Indolderivate als s1p1-rezeptor-agonisten
ATE537151T1 (de) Pyrazolinverbindungen als mineralocorticoidrezeptorantagonisten
EP2459581A4 (en) LIVER X-RECEPTOR AGONISTS
BRPI0715324A2 (pt) Composto de indol
ATE537157T1 (de) Substituierte phenoxy-n-alkylierte thiazoledindione als östrogenassoziierte rezeptor-alpha-modulatoren
EP2030198A4 (en) APPLYING SERVICES TO TRANSCRIPTS
DE602005027307D1 (de) Arylanilinderivate als agonisten des beta2-adrenergen rezeptors
EP1981902A4 (en) ANTAGONISTS OF NOGO RECEPTORS
ATE465169T1 (de) Hemmstoffe des progesteron-rezeptors
ATE538091T1 (de) Tetrahydrocyclopentaäbüindolverbindungen als androgenrezeptormodulatoren
ATE539056T1 (de) Piperidinderivate als agonisten muskariner rezeptoren
ATE555111T1 (de) Chinuclidinol-derivate als muscarinrezeptor- antagonisten
ATE420088T1 (de) Chinolinoncarbonsäureamidverbindungen als 5-ht4- rezeptoragonisten
EP2365749A4 (en) Quinolone NEURO PEPTIDE-S-Receptor Antagonists
ATE477243T1 (de) 2-aminochinoline als 5-ht(5a)- rezeptorantagonisten
BRPI0923237A2 (pt) compostos de 4-azetidinil-1-heteroaril-ciclohexanol antagonistas de ccr2
HRP20160950T1 (hr) Polimorfi antagonista mglur5 receptora
ATE421511T1 (de) Indol-3-carbonyl-spiro-piperidinderivate als antagonisten des v1a-rezeptors
DE602006019624D1 (de) Piperidin-4-yl-pyridazin-3-yl-aminderivate als schnell dissoziierende antagonisten des dopamin-2-rezeptors

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2066628

Country of ref document: EP